Similar articles

• Diabetes drug may activate molecule that triggers cancer growth.

  Printz C. Printz C. Cancer. 2014 May 15;120(10):1445. doi: 10.1002/cncr.28752. Cancer. 2014. PMID: 24802155 No abstract available.
• Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.

  Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, Nakajima A. Hosono K, et al. Mol Carcinog. 2010 Jul;49(7):662-71. doi: 10.1002/mc.20637. Mol Carcinog. 2010. PMID: 20564343
• Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.

  Wysocki PJ, Wierusz-Wysocka B. Wysocki PJ, et al. Expert Rev Mol Diagn. 2010 May;10(4):509-19. doi: 10.1586/erm.10.22. Expert Rev Mol Diagn. 2010. PMID: 20465505 Review.
• Metformin: diamonds are forever.

  Papanas N, Maltezos E, Mikhailidis DP. Papanas N, et al. Expert Opin Pharmacother. 2009 Oct;10(15):2395-7. doi: 10.1517/14656560903176453. Expert Opin Pharmacother. 2009. PMID: 19678795
• Metformin and cancer.

  Rizos CV, Elisaf MS. Rizos CV, et al. Eur J Pharmacol. 2013 Apr 5;705(1-3):96-108. doi: 10.1016/j.ejphar.2013.02.038. Epub 2013 Mar 13. Eur J Pharmacol. 2013. PMID: 23499688 Review.